A doctor’s recent $482 million jury award against Johnson & Johnson and a subsidiary for infringing a drug-eluting cardiac stent patent appears to sidestep at least some recent criticisms about damages from the U.S. Court of Appeals for the Federal Circuit.
An Eastern District of Texas jury handed down the verdict in Saffran v. Johnson & Johnson on Jan. 28. The jury deliberated for two hours before finding that Dr. Bruce Saffran’s patent was valid and that a cardiac stent manufactured by J&J subsidiary Cordis Corp. willfully infringed it. The willful infringement verdict gives the court discretion to treble the amount.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
